Destiny Pharma plc (LON:DEST – Get Free Report) dropped 30.1% on Wednesday . The company traded as low as GBX 2.55 ($0.03) and last traded at GBX 3 ($0.04). Approximately 4,179,453 shares changed hands during trading, an increase of 484% from the average daily volume of 715,908 shares. The stock had previously closed at GBX 4.29 ($0.05).
Destiny Pharma Stock Performance
The stock has a 50-day moving average of GBX 3 and a two-hundred day moving average of GBX 7.18. The company has a market cap of £2.87 million, a P/E ratio of -50.00 and a beta of 0.22.
About Destiny Pharma
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria.
See Also
- Five stocks we like better than Destiny Pharma
- The Role Economic Reports Play in a Successful Investment Strategy
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- What is a Death Cross in Stocks?
- 3 Penny Stocks Ready to Break Out in 2025
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
